tetano
Editor, Senior Moderator
PLoS Pathog
. 2024 Aug 2;20(8):e1012383.
doi: 10.1371/journal.ppat.1012383. Online ahead of print. The S2 subunit of spike encodes diverse targets for functional antibody responses to SARS-CoV-2
Jamie Guenthoer[SUP] 1 [/SUP], Meghan E Garrett[SUP] 1 [/SUP], Michelle Lilly[SUP] 1 [/SUP], Delphine M Depierreux[SUP] 1 [/SUP], Felicitas Ruiz[SUP] 1 [/SUP], Margaret Chi[SUP] 1 [/SUP], Caitlin I Stoddard[SUP] 1 [/SUP], Vrasha Chohan[SUP] 1 [/SUP], Zak A Yaffe[SUP] 1 [/SUP], Kevin Sung[SUP] 2 [/SUP], Duncan Ralph[SUP] 2 [/SUP], Helen Y Chu[SUP] 3 [/SUP], Frederick A Matsen 4th[SUP] 2 4 [/SUP], Julie Overbaugh[SUP] 1 2 [/SUP]
Affiliations
The SARS-CoV-2 virus responsible for the COVID-19 global pandemic has exhibited a striking capacity for viral evolution that drives continued evasion from vaccine and infection-induced immune responses. Mutations in the receptor binding domain of the S1 subunit of the spike glycoprotein have led to considerable escape from antibody responses, reducing the efficacy of vaccines and monoclonal antibody (mAb) therapies. Therefore, there is a need to interrogate more constrained regions of spike, such as the S2 subdomain. Here, we present a collection of S2 mAbs from two SARS-CoV-2 convalescent individuals that target multiple regions in S2, including regions outside of those commonly reported. One of the S2 mAbs, C20.119, which bound to a highly conserved epitope in the fusion peptide, was able to broadly neutralize across SARS-CoV-2 variants, SARS-CoV-1, and closely related zoonotic sarbecoviruses. The majority of the mAbs were non-neutralizing; however, many of them could mediate antibody-dependent cellular cytotoxicity (ADCC) at levels similar to the S1-targeting mAb S309 that was previously authorized for treatment of SARS-CoV-2 infections. Several of the mAbs with ADCC function also bound to spike trimers from other human coronaviruses (HCoVs), such as MERS-CoV and HCoV-HKU1. Our findings suggest S2 mAbs can target diverse epitopes in S2, including functional mAbs with HCoV and sarbecovirus breadth that likely target functionally constrained regions of spike. These mAbs could be developed for potential future pandemics, while also providing insight into ideal epitopes for eliciting a broad HCoV response.
. 2024 Aug 2;20(8):e1012383.
doi: 10.1371/journal.ppat.1012383. Online ahead of print. The S2 subunit of spike encodes diverse targets for functional antibody responses to SARS-CoV-2
Jamie Guenthoer[SUP] 1 [/SUP], Meghan E Garrett[SUP] 1 [/SUP], Michelle Lilly[SUP] 1 [/SUP], Delphine M Depierreux[SUP] 1 [/SUP], Felicitas Ruiz[SUP] 1 [/SUP], Margaret Chi[SUP] 1 [/SUP], Caitlin I Stoddard[SUP] 1 [/SUP], Vrasha Chohan[SUP] 1 [/SUP], Zak A Yaffe[SUP] 1 [/SUP], Kevin Sung[SUP] 2 [/SUP], Duncan Ralph[SUP] 2 [/SUP], Helen Y Chu[SUP] 3 [/SUP], Frederick A Matsen 4th[SUP] 2 4 [/SUP], Julie Overbaugh[SUP] 1 2 [/SUP]
Affiliations
- PMID: 39093891
- DOI: 10.1371/journal.ppat.1012383
The SARS-CoV-2 virus responsible for the COVID-19 global pandemic has exhibited a striking capacity for viral evolution that drives continued evasion from vaccine and infection-induced immune responses. Mutations in the receptor binding domain of the S1 subunit of the spike glycoprotein have led to considerable escape from antibody responses, reducing the efficacy of vaccines and monoclonal antibody (mAb) therapies. Therefore, there is a need to interrogate more constrained regions of spike, such as the S2 subdomain. Here, we present a collection of S2 mAbs from two SARS-CoV-2 convalescent individuals that target multiple regions in S2, including regions outside of those commonly reported. One of the S2 mAbs, C20.119, which bound to a highly conserved epitope in the fusion peptide, was able to broadly neutralize across SARS-CoV-2 variants, SARS-CoV-1, and closely related zoonotic sarbecoviruses. The majority of the mAbs were non-neutralizing; however, many of them could mediate antibody-dependent cellular cytotoxicity (ADCC) at levels similar to the S1-targeting mAb S309 that was previously authorized for treatment of SARS-CoV-2 infections. Several of the mAbs with ADCC function also bound to spike trimers from other human coronaviruses (HCoVs), such as MERS-CoV and HCoV-HKU1. Our findings suggest S2 mAbs can target diverse epitopes in S2, including functional mAbs with HCoV and sarbecovirus breadth that likely target functionally constrained regions of spike. These mAbs could be developed for potential future pandemics, while also providing insight into ideal epitopes for eliciting a broad HCoV response.